Business Context and Reporting Period
This Form 8-K filing by Catalyst Biosciences, Inc. (noted as Gyre Therapeutics in metadata) reports corporate governance and compensation actions taken on October 22, 2015. The report was filed on October 27, 2015.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive and director compensation arrangements.
Material Changes and Compensation Details
Executive Officer Compensation
Effective September 1, 2015, the Compensation Committee approved base salaries, option grants, and bonus targets for fiscal year 2015. The exercise price for all option grants is $4.40 per share.
| Officer | Base Salary | Option Grant (Shares) | Contingent Option (Shares) | Target Bonus |
|---|---|---|---|---|
| Nassim Usman, Ph.D. (CEO) | $440,000 | 71,428 | 153,572 | 50% |
| Edwin L. Madison, Ph.D. (CSO) | $350,000 | 71,428 | 58,572 | 35% |
| Fletcher Payne (CFO) | $316,000 | 71,428 | 28,572 | 35% |
Salary Increases: Dr. Usman received a 10% increase, Dr. Madison an 8% increase, and Mr. Payne a 5% increase over prior compensation (Mr. Payne was not employed in 2014).
Vesting: Options vest monthly over four years, subject to continued service.
Stock Incentive Plan Amendment
The Board approved an amendment to the 2015 Stock Incentive Plan, subject to stockholder approval, increasing annual participant award limitations to:
- 500,000 shares for options and stock appreciation rights.
- 500,000 shares for other awards.
- 75,000 shares for non-employee directors.
Director Compensation Policy
A new policy was adopted for non-employee directors, including:
- Initial Equity Grant: Option to purchase 15,000 shares vesting over three years.
- Annual Retainers: Option to purchase 7,500 shares vesting over one year, plus cash retainers.
Cash Retainer Fees (Annual):
| Role | Member Fee | Chair Fee |
|---|---|---|
| Board of Directors | $35,000 | $60,000 |
| Audit Committee | $7,500 | $15,000 |
| Compensation Committee | $5,000 | $10,000 |
| Governance and Nominating Committee | $3,750 | $7,500 |
Exception: Director Jeff Himawan, Ph.D., declined all compensation in accordance with his investment fund's policies.
Guidance, Risks, and Contingencies
Contingencies: A portion of the executive option grants (contingent options) and the Plan Amendment are subject to stockholder approval. The actual bonus amounts are at the Compensation Committee's discretion based on corporate performance.
Risks: The filing does not explicitly list operational or financial risks, though the reliance on stockholder approval for plan amendments represents a governance contingency.
Key Facts for Investor Verification
- Verify the outcome of the stockholder vote on the 2015 Stock Incentive Plan Amendment, as it affects the validity of contingent option grants.
- Confirm the total number of shares authorized under the amended plan to assess potential dilution.
- Review the specific corporate objectives tied to the executive performance bonuses.
- Monitor the vesting schedules for the new equity grants to understand future dilution timelines.